Entity > Corporation > US > New York City New York > Emmaus Life Sciences
About Emmaus Life Sciences
Emmaus Life Sciences, Inc. is a biopharmaceutical company. Emmaus Life Sciences, Inc. focuses on rare and orphan diseases, such as sickle cell disease.
Emmaus Life Sciences, Inc. Offers Products For The Treatment Of Sickle Cell Disease: Emmaus Life Sciences, Inc. is in clinical development of a patented experimental treatment approach of an orally administered pharmaceutical grade L-glutamine to treat some of the symptoms of sickle cell disease (SCD). Emmaus Life Sciences, Inc.'s lead commercial product is Endari®. The product candidate showed positive clinical results in the completed Phase 3 clinical trial for sickle cell anaemia and sickle SS0 thalassemia.
Emmaus Life Sciences, Inc.’s Founding and Headquarters: Emmaus Life Sciences, Inc. was founded in 2000 by Yutaka Niihara, M.D., M.P.H. Emmaus Life Sciences, Inc. is currently headquartered in Torrance, California, USA.
Industry:
More information about Emmaus Life Sciences
| Company Attribute | Value |
| Name | Emmaus Life Sciences |
| Url | emmausmedical |
Emmaus Life Sciences
New York City, US
24 Aug 2023
Emmaus Life Sciences
EMI Holding, Inc. (Pharmaceutical company)
Emmaus Life Sciences, Inc. is a biopharmaceutical company engaged in the discovery, development and commercialization of innovative treatments and therapies primarily for rare and orphan disease. It is initially focusing its product development efforts in sickle cell disease, a genetic disorder.
-
Headquarters : Torrance, CA
-
Stock price : EMMA (OTCMKTS) $0.16 +0.01 (+4.92%)Aug 23, 4:00 PM EDT - Disclaimer
-
Subsidiaries : Emmaus Medical, MYnd Analytics California, MORE
-
Founded : 1987